United States Antisense and RNAi Therapeutics Market Report 2017

November 2017 | 109 pages | ID: UFB0D38EA97WEN
QYResearch

Abstracts

In this report, the United States Antisense and RNAi Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Antisense and RNAi Therapeutics in these regions, from 2012 to 2022 (forecast).

United States Antisense and RNAi Therapeutics market competition by top manufacturers/players, with Antisense and RNAi Therapeutics sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Glaxo Smith Kline
• Sanofi Aventis / Genzyme
• Isis Pharmaceuticals/ Ionis Pharmaceuticals
• Arbutus Biopharma Ltd.
• Silence Therapeutics
• Bio-Path Holdings Inc.
• Calando Pharmaceuticals
• ICo Therapeutics
• Quark Pharmaceuticals
• Rexhan Pharmaceuticals
• Biomarin/Prosensa
• Regulus Therapeutics
• Rxi Pharmaceuticals
• Silenseed
• Dicerna Pharmaceuticals
• Sirnaomics Inc

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• RNA interference
• SiRNA
• MiRNA
• Antisense RNA

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Antisense and RNAi Therapeutics for each application, including

• Oncology
• Cardiovascular
• Renal
• Neurodegenerative
• Respiratory
• Genetic
• Infectious Diseases

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Antisense and RNAi Therapeutics Market Report 2017

1 ANTISENSE AND RNAI THERAPEUTICS OVERVIEW

1.1 Product Overview and Scope of Antisense and RNAi Therapeutics
1.2 Classification of Antisense and RNAi Therapeutics by Product Category
  1.2.1 United States Antisense and RNAi Therapeutics Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Antisense and RNAi Therapeutics Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 RNA interference
  1.2.4 SiRNA
  1.2.5 MiRNA
  1.2.6 Antisense RNA
1.3 United States Antisense and RNAi Therapeutics Market by Application/End Users
  1.3.1 United States Antisense and RNAi Therapeutics Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Oncology
  1.3.3 Cardiovascular
  1.3.4 Renal
  1.3.5 Neurodegenerative
  1.3.6 Respiratory
  1.3.7 Genetic
  1.3.8 Infectious Diseases
1.4 United States Antisense and RNAi Therapeutics Market by Region
  1.4.1 United States Antisense and RNAi Therapeutics Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Antisense and RNAi Therapeutics Status and Prospect (2012-2022)
  1.4.3 Southwest Antisense and RNAi Therapeutics Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Antisense and RNAi Therapeutics Status and Prospect (2012-2022)
  1.4.5 New England Antisense and RNAi Therapeutics Status and Prospect (2012-2022)
  1.4.6 The South Antisense and RNAi Therapeutics Status and Prospect (2012-2022)
  1.4.7 The Midwest Antisense and RNAi Therapeutics Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Antisense and RNAi Therapeutics (2012-2022)
  1.5.1 United States Antisense and RNAi Therapeutics Sales and Growth Rate (2012-2022)
  1.5.2 United States Antisense and RNAi Therapeutics Revenue and Growth Rate (2012-2022)

2 UNITED STATES ANTISENSE AND RNAI THERAPEUTICS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Antisense and RNAi Therapeutics Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Antisense and RNAi Therapeutics Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Antisense and RNAi Therapeutics Average Price by Players/Suppliers (2012-2017)
2.4 United States Antisense and RNAi Therapeutics Market Competitive Situation and Trends
  2.4.1 United States Antisense and RNAi Therapeutics Market Concentration Rate
  2.4.2 United States Antisense and RNAi Therapeutics Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Antisense and RNAi Therapeutics Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES ANTISENSE AND RNAI THERAPEUTICS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Antisense and RNAi Therapeutics Sales and Market Share by Region (2012-2017)
3.2 United States Antisense and RNAi Therapeutics Revenue and Market Share by Region (2012-2017)
3.3 United States Antisense and RNAi Therapeutics Price by Region (2012-2017)

4 UNITED STATES ANTISENSE AND RNAI THERAPEUTICS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Antisense and RNAi Therapeutics Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Antisense and RNAi Therapeutics Revenue and Market Share by Type (2012-2017)
4.3 United States Antisense and RNAi Therapeutics Price by Type (2012-2017)
4.4 United States Antisense and RNAi Therapeutics Sales Growth Rate by Type (2012-2017)

5 UNITED STATES ANTISENSE AND RNAI THERAPEUTICS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Antisense and RNAi Therapeutics Sales and Market Share by Application (2012-2017)
5.2 United States Antisense and RNAi Therapeutics Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES ANTISENSE AND RNAI THERAPEUTICS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Glaxo Smith Kline
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Antisense and RNAi Therapeutics Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Glaxo Smith Kline Antisense and RNAi Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Sanofi Aventis / Genzyme
  6.2.2 Antisense and RNAi Therapeutics Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Sanofi Aventis / Genzyme Antisense and RNAi Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
  6.3.2 Antisense and RNAi Therapeutics Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense and RNAi Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Arbutus Biopharma Ltd.
  6.4.2 Antisense and RNAi Therapeutics Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Arbutus Biopharma Ltd. Antisense and RNAi Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Silence Therapeutics
  6.5.2 Antisense and RNAi Therapeutics Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Bio-Path Holdings Inc.
  6.6.2 Antisense and RNAi Therapeutics Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Bio-Path Holdings Inc. Antisense and RNAi Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Calando Pharmaceuticals
  6.7.2 Antisense and RNAi Therapeutics Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Calando Pharmaceuticals Antisense and RNAi Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 ICo Therapeutics
  6.8.2 Antisense and RNAi Therapeutics Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 ICo Therapeutics Antisense and RNAi Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Quark Pharmaceuticals
  6.9.2 Antisense and RNAi Therapeutics Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Quark Pharmaceuticals Antisense and RNAi Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Rexhan Pharmaceuticals
  6.10.2 Antisense and RNAi Therapeutics Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Rexhan Pharmaceuticals Antisense and RNAi Therapeutics Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Biomarin/Prosensa
6.12 Regulus Therapeutics
6.13 Rxi Pharmaceuticals
6.14 Silenseed
6.15 Dicerna Pharmaceuticals
6.16 Sirnaomics Inc

7 ANTISENSE AND RNAI THERAPEUTICS MANUFACTURING COST ANALYSIS

7.1 Antisense and RNAi Therapeutics Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Antisense and RNAi Therapeutics

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Antisense and RNAi Therapeutics Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Antisense and RNAi Therapeutics Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES ANTISENSE AND RNAI THERAPEUTICS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Antisense and RNAi Therapeutics Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Antisense and RNAi Therapeutics Sales Volume Forecast by Type (2017-2022)
11.3 United States Antisense and RNAi Therapeutics Sales Volume Forecast by Application (2017-2022)
11.4 United States Antisense and RNAi Therapeutics Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Antisense and RNAi Therapeutics
Figure United States Antisense and RNAi Therapeutics Market Size (K Units) by Type (2012-2022)
Figure United States Antisense and RNAi Therapeutics Sales Volume Market Share by Type (Product Category) in 2016
Figure RNA interference Product Picture
Figure SiRNA Product Picture
Figure MiRNA Product Picture
Figure Antisense RNA Product Picture
Figure United States Antisense and RNAi Therapeutics Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Antisense and RNAi Therapeutics by Application in 2016
Figure Oncology Examples
Table Key Downstream Customer in Oncology
Figure Cardiovascular Examples
Table Key Downstream Customer in Cardiovascular
Figure Renal Examples
Table Key Downstream Customer in Renal
Figure Neurodegenerative Examples
Table Key Downstream Customer in Neurodegenerative
Figure Respiratory Examples
Table Key Downstream Customer in Respiratory
Figure Genetic Examples
Table Key Downstream Customer in Genetic
Figure Infectious Diseases Examples
Table Key Downstream Customer in Infectious Diseases
Figure United States Antisense and RNAi Therapeutics Market Size (Million USD) by Region (2012-2022)
Figure The West Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Antisense and RNAi Therapeutics Sales (K Units) and Growth Rate (2012-2022)
Figure United States Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Antisense and RNAi Therapeutics Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Antisense and RNAi Therapeutics Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Antisense and RNAi Therapeutics Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Antisense and RNAi Therapeutics Sales Share by Players/Suppliers
Figure 2017 United States Antisense and RNAi Therapeutics Sales Share by Players/Suppliers
Figure United States Antisense and RNAi Therapeutics Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Antisense and RNAi Therapeutics Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Antisense and RNAi Therapeutics Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Antisense and RNAi Therapeutics Revenue Share by Players/Suppliers
Figure 2017 United States Antisense and RNAi Therapeutics Revenue Share by Players/Suppliers
Table United States Market Antisense and RNAi Therapeutics Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Antisense and RNAi Therapeutics Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Antisense and RNAi Therapeutics Market Share of Top 3 Players/Suppliers
Figure United States Antisense and RNAi Therapeutics Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Antisense and RNAi Therapeutics Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Antisense and RNAi Therapeutics Product Category
Table United States Antisense and RNAi Therapeutics Sales (K Units) by Region (2012-2017)
Table United States Antisense and RNAi Therapeutics Sales Share by Region (2012-2017)
Figure United States Antisense and RNAi Therapeutics Sales Share by Region (2012-2017)
Figure United States Antisense and RNAi Therapeutics Sales Market Share by Region in 2016
Table United States Antisense and RNAi Therapeutics Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Antisense and RNAi Therapeutics Revenue Share by Region (2012-2017)
Figure United States Antisense and RNAi Therapeutics Revenue Market Share by Region (2012-2017)
Figure United States Antisense and RNAi Therapeutics Revenue Market Share by Region in 2016
Table United States Antisense and RNAi Therapeutics Price (USD/Unit) by Region (2012-2017)
Table United States Antisense and RNAi Therapeutics Sales (K Units) by Type (2012-2017)
Table United States Antisense and RNAi Therapeutics Sales Share by Type (2012-2017)
Figure United States Antisense and RNAi Therapeutics Sales Share by Type (2012-2017)
Figure United States Antisense and RNAi Therapeutics Sales Market Share by Type in 2016
Table United States Antisense and RNAi Therapeutics Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Antisense and RNAi Therapeutics Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Antisense and RNAi Therapeutics by Type (2012-2017)
Figure Revenue Market Share of Antisense and RNAi Therapeutics by Type in 2016
Table United States Antisense and RNAi Therapeutics Price (USD/Unit) by Types (2012-2017)
Figure United States Antisense and RNAi Therapeutics Sales Growth Rate by Type (2012-2017)
Table United States Antisense and RNAi Therapeutics Sales (K Units) by Application (2012-2017)
Table United States Antisense and RNAi Therapeutics Sales Market Share by Application (2012-2017)
Figure United States Antisense and RNAi Therapeutics Sales Market Share by Application (2012-2017)
Figure United States Antisense and RNAi Therapeutics Sales Market Share by Application in 2016
Table United States Antisense and RNAi Therapeutics Sales Growth Rate by Application (2012-2017)
Figure United States Antisense and RNAi Therapeutics Sales Growth Rate by Application (2012-2017)
Table Glaxo Smith Kline Basic Information List
Table Glaxo Smith Kline Antisense and RNAi Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Glaxo Smith Kline Antisense and RNAi Therapeutics Sales Growth Rate (2012-2017)
Figure Glaxo Smith Kline Antisense and RNAi Therapeutics Sales Market Share in United States (2012-2017)
Figure Glaxo Smith Kline Antisense and RNAi Therapeutics Revenue Market Share in United States (2012-2017)
Table Sanofi Aventis / Genzyme Basic Information List
Table Sanofi Aventis / Genzyme Antisense and RNAi Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sanofi Aventis / Genzyme Antisense and RNAi Therapeutics Sales Growth Rate (2012-2017)
Figure Sanofi Aventis / Genzyme Antisense and RNAi Therapeutics Sales Market Share in United States (2012-2017)
Figure Sanofi Aventis / Genzyme Antisense and RNAi Therapeutics Revenue Market Share in United States (2012-2017)
Table Isis Pharmaceuticals/ Ionis Pharmaceuticals Basic Information List
Table Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense and RNAi Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense and RNAi Therapeutics Sales Growth Rate (2012-2017)
Figure Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense and RNAi Therapeutics Sales Market Share in United States (2012-2017)
Figure Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense and RNAi Therapeutics Revenue Market Share in United States (2012-2017)
Table Arbutus Biopharma Ltd. Basic Information List
Table Arbutus Biopharma Ltd. Antisense and RNAi Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Arbutus Biopharma Ltd. Antisense and RNAi Therapeutics Sales Growth Rate (2012-2017)
Figure Arbutus Biopharma Ltd. Antisense and RNAi Therapeutics Sales Market Share in United States (2012-2017)
Figure Arbutus Biopharma Ltd. Antisense and RNAi Therapeutics Revenue Market Share in United States (2012-2017)
Table Silence Therapeutics Basic Information List
Table Silence Therapeutics Antisense and RNAi Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Silence Therapeutics Antisense and RNAi Therapeutics Sales Growth Rate (2012-2017)
Figure Silence Therapeutics Antisense and RNAi Therapeutics Sales Market Share in United States (2012-2017)
Figure Silence Therapeutics Antisense and RNAi Therapeutics Revenue Market Share in United States (2012-2017)
Table Bio-Path Holdings Inc. Basic Information List
Table Bio-Path Holdings Inc. Antisense and RNAi Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Bio-Path Holdings Inc. Antisense and RNAi Therapeutics Sales Growth Rate (2012-2017)
Figure Bio-Path Holdings Inc. Antisense and RNAi Therapeutics Sales Market Share in United States (2012-2017)
Figure Bio-Path Holdings Inc. Antisense and RNAi Therapeutics Revenue Market Share in United States (2012-2017)
Table Calando Pharmaceuticals Basic Information List
Table Calando Pharmaceuticals Antisense and RNAi Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Calando Pharmaceuticals Antisense and RNAi Therapeutics Sales Growth Rate (2012-2017)
Figure Calando Pharmaceuticals Antisense and RNAi Therapeutics Sales Market Share in United States (2012-2017)
Figure Calando Pharmaceuticals Antisense and RNAi Therapeutics Revenue Market Share in United States (2012-2017)
Table ICo Therapeutics Basic Information List
Table ICo Therapeutics Antisense and RNAi Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure ICo Therapeutics Antisense and RNAi Therapeutics Sales Growth Rate (2012-2017)
Figure ICo Therapeutics Antisense and RNAi Therapeutics Sales Market Share in United States (2012-2017)
Figure ICo Therapeutics Antisense and RNAi Therapeutics Revenue Market Share in United States (2012-2017)
Table Quark Pharmaceuticals Basic Information List
Table Quark Pharmaceuticals Antisense and RNAi Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Quark Pharmaceuticals Antisense and RNAi Therapeutics Sales Growth Rate (2012-2017)
Figure Quark Pharmaceuticals Antisense and RNAi Therapeutics Sales Market Share in United States (2012-2017)
Figure Quark Pharmaceuticals Antisense and RNAi Therapeutics Revenue Market Share in United States (2012-2017)
Table Rexhan Pharmaceuticals Basic Information List
Table Rexhan Pharmaceuticals Antisense and RNAi Therapeutics Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Rexhan Pharmaceuticals Antisense and RNAi Therapeutics Sales Growth Rate (2012-2017)
Figure Rexhan Pharmaceuticals Antisense and RNAi Therapeutics Sales Market Share in United States (2012-2017)
Figure Rexhan Pharmaceuticals Antisense and RNAi Therapeutics Revenue Market Share in United States (2012-2017)
Table Biomarin/Prosensa Basic Information List
Table Regulus Therapeutics Basic Information List
Table Rxi Pharmaceuticals Basic Information List
Table Silenseed Basic Information List
Table Dicerna Pharmaceuticals Basic Information List
Table Sirnaomics Inc Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Antisense and RNAi Therapeutics
Figure Manufacturing Process Analysis of Antisense and RNAi Therapeutics
Figure Antisense and RNAi Therapeutics Industrial Chain Analysis
Table Raw Materials Sources of Antisense and RNAi Therapeutics Major Players/Suppliers in 2016
Table Major Buyers of Antisense and RNAi Therapeutics
Table Distributors/Traders List
Figure United States Antisense and RNAi Therapeutics Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Antisense and RNAi Therapeutics Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Antisense and RNAi Therapeutics Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Antisense and RNAi Therapeutics Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Antisense and RNAi Therapeutics Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Antisense and RNAi Therapeutics Sales Volume (K Units) Forecast by Type in 2022
Table United States Antisense and RNAi Therapeutics Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Antisense and RNAi Therapeutics Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Antisense and RNAi Therapeutics Sales Volume (K Units) Forecast by Application in 2022
Table United States Antisense and RNAi Therapeutics Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Antisense and RNAi Therapeutics Sales Volume Share Forecast by Region (2017-2022)
Figure United States Antisense and RNAi Therapeutics Sales Volume Share Forecast by Region (2017-2022)
Figure United States Antisense and RNAi Therapeutics Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources